The major, Switzerland-based, global pharmaceutical company Novartis has just agreed to acquire Endocyte — the developer of both Lu-177- PSMA-617 and Ac-225-PSMA-617, which are in clinical trials for the treatment of advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: Endocyte, Lu-177. Ac-225, Novartis, PSMA, radiopharmaceutical | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 